Isotechnika's share price rose by 12.5% to Can$0.135 after the Canadian firm announced that it had licensed out its lead drug for a secondary indication. Vifor Pharma, the speciality pharma business of Swiss firm Galenica, has acquired rights to voclosporin for lupus and all proteinuric nephrology indications; Isotechnika is developing it primarily for the prevention of kidney transplant rejection.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?